| 2 -0.35 (-14.89%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.49  |
1-year : | 2.87 |
| Resists | First : | 2.13 |
Second : | 2.46 |
| Pivot price | 1.91 |
|||
| Supports | First : | 1.61 |
Second : | 1.33 |
| MAs | MA(5) : | 1.98 |
MA(20) : | 1.88 |
| MA(100) : | 2.74 |
MA(250) : | 2.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 60.5 |
D(3) : | 44.1 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 4.5 | Low : | 1.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AIMD ] has closed below upper band by 36.4%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.24 - 2.26 | 2.26 - 2.27 |
| Low: | 1.97 - 1.99 | 1.99 - 2 |
| Close: | 1.98 - 2 | 2 - 2.02 |
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Thu, 29 Jan 2026
Insider Sell: Taiwan Carbon Nano Technology Corp Sells 46,000 Sh - GuruFocus
Thu, 29 Jan 2026
Taiwan carbon nano tech sells Ainos (AIMD) shares for $99,806 By Investing.com - Investing.com South Africa
Wed, 28 Jan 2026
12 Information Technology Stocks Moving In Wednesday's Intraday Session - Benzinga
Wed, 28 Jan 2026
Ainos Expands SmellTech Strategy with Trusval Agreement - StocksToTrade
Tue, 20 Jan 2026
Ainos to Participate in Fireside Chat with Water Tower Research on January 26, 2026 - Chartmill
Mon, 12 Jan 2026
Inside the 'AI nose' tech spreading from labs into chip factories in 2026 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 2.92e+006 (%) |
| Held by Institutions | 65.5 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.56e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -128 % |
| Return on Assets (ttm) | 481.4 % |
| Return on Equity (ttm) | -33.2 % |
| Qtrly Rev. Growth | 113040 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -43.33 |
| EBITDA (p.s.) | 37995.9 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 2.34 |
| Dividend | 0 |
| Forward Dividend | 20240 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|